Considering the promising evidence for both the predictive and prognostic value of K17 in several cancer types, we believe future studies should focus on (1) assay validation, as this may assist in streamlining clinical translation; and (2) using prospective cohorts or retrospective analyses of well-curated biospecimens linked to high-quality clinical outcome data [90]. The gene discussed is KRT17; the disease is cancer.